Angiotensin‐converting enzyme inhibitors attenuate circulating CAF22 and physical decline in congestive heart failure: Diagnostic implications of CAF22

Firdos Ahmad,Asima Karim,Javaidullah Khan,Rizwan Qaisar
DOI: https://doi.org/10.1111/bcp.16252
2024-09-29
British Journal of Clinical Pharmacology
Abstract:Aims Age‐associated muscle loss, termed sarcopenia is the major cause of physical disability in patients with congestive heart failure (CHF). Angiotensin‐converting enzyme inhibitors (ACEi) are commonly used to treat CHF patients; however, their impacts on the neuromuscular junction (NMJ) and sarcopenia in CHF patients remain poorly understood. We aim to investigate the potential impact of ACEi on NMJ and CHF‐induced sarcopenia. Methods The cardiac function, short physical performance battery, handgrip strength (HGS), appendicular skeletal mass index, gait speed (GS) and plasma c‐terminal agrin fragment‐22 (CAF22), a marker of NMJ degradation, were assessed in controls (n = 81) and CHF patients treated with (n = 134) or without (n = 145) ACEi. Results Irrespective of treatment, HGS and GS, indicators of sarcopenia, were profoundly declined in the patients with CHF vs. controls. However, patients on ACEi demonstrated significantly better HGS and GS compared to non‐ACEi patients (P
pharmacology & pharmacy
What problem does this paper attempt to address?